Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 159 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Follow-Up Questions
Who is the CEO of Molecular Partners AG?
Dr. Patrick Amstutz is the Chief Executive Officer of Molecular Partners AG, joining the firm since 2006.
What is the price performance of MOLN stock?
The current price of MOLN is $3.69, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Molecular Partners AG?
Molecular Partners AG belongs to Biotechnology industry and the sector is Health Care
What is Molecular Partners AG market cap?
Molecular Partners AG's current market cap is $136.0M
Is Molecular Partners AG a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Molecular Partners AG, including 3 strong buy, 4 buy, 2 hold, 0 sell, and 3 strong sell
